Seaport Therapeutics is a neuropsychiatric drug company that PureTech launched on April 9, 2024. STAT's Andrew Joseph reported that it came from the team behind Karuna and that Daphne Zohar, the founding CEO of PureTech, would lead it. Seaport raised a $100 million Series A round, backed by the same investors who first funded Karuna: ARCH Venture Partners, Sofinnova Investments and Third Rock Ventures.[3],[2],[1],[4]
Chemical & Engineering News described the round as oversubscribed and led by ARCH Venture Partners and Sofinnova, with Third Rock Ventures and PureTech also participating. It said Zohar would serve as Seaport's CEO and that Steven Paul, former CEO of Karuna, would chair the board.[4]
BioPharma Dive explains that Seaport's Glyph platform attaches drugs to dietary fat molecules. This reroutes them to the lymphatic system so more of the drug keeps circulating through the body, with fewer side effects. The outlet says the most advanced candidate at launch was a prodrug of allopregnanolone, being developed for anxious depression.[2]
The launch came with a leadership change at PureTech. BioPharma Dive reports that Zohar stepped down from PureTech's board to lead Seaport. PureTech senior executive Bharatt Chowrira became CEO of PureTech, and Eric Elenko, a co-founder, was promoted to president.[2]